Zealand and Roche's Amylin Peaks at Middle Dose in Milan Data

Fuller Phase 2 obesity data for Zealand Pharma and Roche's amylin analog presented at the EASD conference in Milan on Tuesday showed the best weight-loss result at the middle dose and still trailed Eli Lilly's competing amylin candidate, with Roche's ADR (RHHBY) closing at 53.37, down 1.98%, on 29 September 2026.

The fuller picture arrived, and it did not rewrite the March verdict. Data presented Tuesday at the European Association for the Study of Diabetes annual meeting in Milan showed that the amylin analog being developed by Zealand Pharma (ZLDPF) and Roche (RHHBY) produced its best weight-loss result at the middle dose tested in its Phase 2 obesity trial — and that the drug still trails the amylin candidate in development at Eli Lilly (LLY).

That combination — a dose-response curve that does not climb cleanly with dose, and a comparison that favors the largest company in metabolic medicine — is the reason this readout matters well beyond one conference session. Investors had already marked the program down when topline numbers landed in March and were widely regarded as disappointing. The detailed presentation in Milan was the chance to change that reading. It did not.

Why a middle dose beating a high dose is the awkward result

In early obesity trials, drug developers want to see weight loss increase steadily as the dose increases. That pattern tells them the mechanism is doing what they think it is doing and that there is headroom to push further in Phase 3, where the goal is usually a bigger number over a longer treatment period.

When the middle dose outperforms, the explanation is usually one of two things, and neither is flattering. Either tolerability at the top dose caused enough patients to reduce their dose or stop treatment that the average weight loss was dragged down, or the biology genuinely plateaus. The first problem is sometimes solvable with slower dose escalation. The second is not solvable at all. Until the sponsors show otherwise, the market tends to assume the less convenient interpretation.

Amylin is a hormone released alongside insulin that helps signal fullness and slows stomach emptying. Analogs of it have become the most closely watched follow-on class in obesity because they promise a different route to appetite suppression than the GLP-1 drugs that dominate the market — potentially with a better side-effect profile, potentially in combination with a GLP-1. That is the prize. The Zealand–Roche asset is one of the most advanced attempts at it, which is precisely why a muted dose curve carries weight.

Lilly sets the bar, again

The comparison that framed the Milan session was with Eli Lilly's amylin program, which the new data still trails. Lilly has spent the past several years converting incumbency in incretin medicines into a standing assumption: that whatever the field produces, Lilly's version will land at or near the front. Every competing readout is now scored against that assumption rather than against placebo alone.

For Roche, the stakes are strategic rather than existential. The Swiss group came into obesity through acquisition and partnership precisely because it had no meaningful presence in the category, and the Zealand collaboration was one of the bets meant to close that gap. A candidate that works but works less well than Lilly's is not worthless — obesity is large enough to support multiple products, and combination use is a live commercial path — but it changes the pricing and positioning conversation before a Phase 3 program has even begun.

For Zealand, the Danish developer, the calculus is sharper. A partnered asset is the company's most visible value driver, and partner economics on a second-best molecule look different from partner economics on a leader. The detailed coverage of the Milan presentation from Endpoints News framed the update as a fuller version of a disappointment rather than a rehabilitation of one.

How the three stocks finished the session

Trading on 29 September 2026 closed with the three names pointing in different directions, though none dramatically. Roche's U.S.-listed shares last traded at 53.37, down 1.98% from a previous close of 54.45, within a session range of 53.08 to 53.62 — a decline of 1.08 on the day. Zealand's U.S. quote was static at 41.99, unchanged on the session, with no intraday range at all, a hallmark of a thinly traded over-the-counter listing where the American line does not reprice with every tick of the primary market. Eli Lilly closed at 1184.63, essentially flat at -0.01% against a previous close of 1184.78, having traveled between 1168.47 and 1192.94 during the day.

Those moves happened against an unremarkable broad tape. The S&P 500 tracker closed at $764.20, off 0.18%; the Nasdaq 100 tracker finished at $737.93, up 0.19%; and the Dow tracker ended at $512.88, down 0.22%. In other words, nothing in the index backdrop explains Roche's underperformance on the day.

A caution on reading too much into the Zealand print: a flat over-the-counter quote is an absence of information, not a verdict. The meaningful price discovery for a Copenhagen-listed developer happens on its home exchange, and conference presentations delivered in the European evening frequently land in the next local session.

What the sponsors have to answer next

Three questions will determine whether this program advances on ambitious terms or modest ones.

• Was the top dose limited by tolerability or by biology? The discontinuation and dose-reduction pattern at the highest dose is the single most informative detail, because it separates a fixable titration problem from a ceiling.
• Does a slower escalation schedule recover the lost effect? This is a standard remedy in the incretin class and would be the obvious design change heading into a larger study.
• Is the future here monotherapy or combination? If the amylin analog's best commercial life is alongside a GLP-1 rather than against one, the relevant benchmark stops being Lilly's standalone amylin data and becomes the combined regimen.

There is also a broader read for the sector. Amylin was supposed to be the clean second act of obesity drug development — a mechanism with room to differentiate on tolerability rather than raw efficacy. A dose curve that flattens in the middle suggests that room may be narrower than the enthusiasm of the past two years implied, and that the gap between the leaders and everyone else in metabolic disease is not closing quickly.

Watch for the Phase 3 design disclosure and any updated partnership language from either sponsor. Those documents, more than the conference slides, will reveal how much confidence Roche and Zealand still place in the molecule.

Key facts

• RHHBY last close: 53.37, -1.98% (29 Sep 2026, 20:00 GMT)
• ZLDPF last close: 41.99, unchanged on the day (29 Sep 2026, 20:00 GMT)
• LLY last close: 1184.63, -0.01% (29 Sep 2026, 20:00 GMT)
• Event: Full Phase 2 obesity data presented at EASD, Milan, Tuesday

Frequently asked questions

What did the Zealand and Roche amylin data show?

Fuller Phase 2 obesity results presented at the EASD conference in Milan on Tuesday showed the amylin analog produced its strongest weight-loss effect at the middle dose tested, rather than the highest, and that the weight loss achieved still trails Eli Lilly's competing amylin candidate. Topline data from the same trial reported in March had already been regarded as disappointing.

Why does a middle dose performing best matter?

Developers generally want weight loss to increase steadily with dose, which signals headroom for larger effects in later-stage trials. When the middle dose wins, it usually means either that side effects at the top dose caused patients to reduce or stop treatment, or that the biological effect plateaus. The first can sometimes be fixed with slower dose escalation; the second cannot.

What is an amylin analog?

Amylin is a hormone released alongside insulin that promotes a feeling of fullness and slows how quickly the stomach empties. Drugs that mimic it, called amylin analogs, are being developed as the next wave of obesity treatments after GLP-1 medicines, either on their own or in combination, with the hope of good weight loss and better tolerability.

How did the three stocks close on 29 September 2026?

Roche's U.S. listing (RHHBY) closed at 53.37, down 1.98% from a previous close of 54.45. Zealand's U.S. quote (ZLDPF) was unchanged at 41.99 with no intraday range, typical of a thinly traded over-the-counter line. Eli Lilly (LLY) finished at 1184.63, effectively flat at -0.01%, after trading between 1168.47 and 1192.94.

Does this end the Zealand and Roche obesity program?

Nothing in the Milan presentation indicates the program stops. Obesity is a large enough market to support several products, and amylin analogs may ultimately be used in combination with GLP-1 drugs rather than against them. But a flatter dose curve and a result behind Lilly's affect how the asset is valued and positioned before Phase 3 begins.

What should investors watch next?

The most informative disclosures ahead are the discontinuation and dose-reduction figures at the highest dose, which separate a tolerability problem from a biological ceiling; the design of any Phase 3 study, particularly whether escalation is slowed; and any updated language from Roche or Zealand about the terms and scope of their collaboration.

Sources

• #EASD26: Zealand and Roche's amylin works best at middle dose, trails Lilly's — Endpoints News

Photo: crystal710 · Pixabay Content License — source